nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—mammary gland—lung cancer	0.016	0.108	CbGeAlD
Lithium—IMPA2—respiratory system—lung cancer	0.0125	0.0842	CbGeAlD
Lithium—GSK3B—respiratory system—lung cancer	0.0123	0.0826	CbGeAlD
Lithium—IMPA2—bronchus—lung cancer	0.0103	0.0693	CbGeAlD
Lithium—GSK3B—epithelium—lung cancer	0.0102	0.069	CbGeAlD
Lithium—IMPA2—trachea—lung cancer	0.00924	0.0622	CbGeAlD
Lithium—GSK3A—bronchus—lung cancer	0.00877	0.0591	CbGeAlD
Lithium—IMPA2—cardiac atrium—lung cancer	0.00868	0.0584	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—lung cancer	0.00862	1	CbGdCrCtD
Lithium—GSK3A—trachea—lung cancer	0.00788	0.0531	CbGeAlD
Lithium—GSK3A—cardiac atrium—lung cancer	0.0074	0.0498	CbGeAlD
Lithium—IMPA2—bone marrow—lung cancer	0.00732	0.0493	CbGeAlD
Lithium—IMPA2—lung—lung cancer	0.00664	0.0447	CbGeAlD
Lithium—GSK3B—lung—lung cancer	0.00651	0.0438	CbGeAlD
Lithium—GSK3A—bone marrow—lung cancer	0.00625	0.0421	CbGeAlD
Lithium—GSK3A—lung—lung cancer	0.00566	0.0381	CbGeAlD
Lithium—IMPA2—lymph node—lung cancer	0.00454	0.0306	CbGeAlD
Lithium—GSK3B—lymph node—lung cancer	0.00445	0.03	CbGeAlD
Lithium—GSK3A—lymph node—lung cancer	0.00387	0.0261	CbGeAlD
Lithium—Asthenia—Erlotinib—lung cancer	0.000341	0.00101	CcSEcCtD
Lithium—Discomfort—Gemcitabine—lung cancer	0.000341	0.00101	CcSEcCtD
Lithium—Oedema—Irinotecan—lung cancer	0.000339	0.001	CcSEcCtD
Lithium—Feeling abnormal—Vinorelbine—lung cancer	0.000339	0.001	CcSEcCtD
Lithium—Diarrhoea—Vinblastine—lung cancer	0.000339	0.001	CcSEcCtD
Lithium—Dysgeusia—Etoposide—lung cancer	0.000339	0.001	CcSEcCtD
Lithium—Gastrointestinal pain—Vinorelbine—lung cancer	0.000336	0.000994	CcSEcCtD
Lithium—Flatulence—Paclitaxel—lung cancer	0.000334	0.000987	CcSEcCtD
Lithium—Shock—Irinotecan—lung cancer	0.000334	0.000986	CcSEcCtD
Lithium—Dysgeusia—Paclitaxel—lung cancer	0.000332	0.000981	CcSEcCtD
Lithium—Oedema—Gemcitabine—lung cancer	0.000331	0.000977	CcSEcCtD
Lithium—Diarrhoea—Topotecan—lung cancer	0.000329	0.000972	CcSEcCtD
Lithium—Dizziness—Vinblastine—lung cancer	0.000327	0.000967	CcSEcCtD
Lithium—Convulsion—Cisplatin—lung cancer	0.000327	0.000966	CcSEcCtD
Lithium—Diarrhoea—Erlotinib—lung cancer	0.000326	0.000962	CcSEcCtD
Lithium—Abdominal pain—Vinorelbine—lung cancer	0.000325	0.000961	CcSEcCtD
Lithium—Body temperature increased—Vinorelbine—lung cancer	0.000325	0.000961	CcSEcCtD
Lithium—Anorexia—Irinotecan—lung cancer	0.000323	0.000956	CcSEcCtD
Lithium—Ataxia—Methotrexate—lung cancer	0.000323	0.000956	CcSEcCtD
Lithium—Vision blurred—Paclitaxel—lung cancer	0.00032	0.000944	CcSEcCtD
Lithium—Dizziness—Topotecan—lung cancer	0.000318	0.00094	CcSEcCtD
Lithium—Tremor—Paclitaxel—lung cancer	0.000318	0.000939	CcSEcCtD
Lithium—Discomfort—Cisplatin—lung cancer	0.000318	0.000938	CcSEcCtD
Lithium—Hypotension—Irinotecan—lung cancer	0.000317	0.000937	CcSEcCtD
Lithium—Anorexia—Gemcitabine—lung cancer	0.000315	0.000931	CcSEcCtD
Lithium—Vomiting—Vinblastine—lung cancer	0.000315	0.00093	CcSEcCtD
Lithium—Dizziness—Erlotinib—lung cancer	0.000315	0.00093	CcSEcCtD
Lithium—Agitation—Paclitaxel—lung cancer	0.000312	0.000921	CcSEcCtD
Lithium—Vertigo—Etoposide—lung cancer	0.000311	0.000918	CcSEcCtD
Lithium—Headache—Vinblastine—lung cancer	0.00031	0.000916	CcSEcCtD
Lithium—Angioedema—Paclitaxel—lung cancer	0.00031	0.000915	CcSEcCtD
Lithium—Hypotension—Gemcitabine—lung cancer	0.000309	0.000913	CcSEcCtD
Lithium—Oedema—Cisplatin—lung cancer	0.000308	0.00091	CcSEcCtD
Lithium—Vomiting—Topotecan—lung cancer	0.000306	0.000904	CcSEcCtD
Lithium—Vertigo—Paclitaxel—lung cancer	0.000305	0.0009	CcSEcCtD
Lithium—Syncope—Paclitaxel—lung cancer	0.000304	0.000898	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—lung cancer	0.000304	0.000898	CcSEcCtD
Lithium—Lethargy—Doxorubicin—lung cancer	0.000304	0.000898	CcSEcCtD
Lithium—Rash—Topotecan—lung cancer	0.000303	0.000896	CcSEcCtD
Lithium—Dermatitis—Topotecan—lung cancer	0.000303	0.000895	CcSEcCtD
Lithium—Vomiting—Erlotinib—lung cancer	0.000303	0.000894	CcSEcCtD
Lithium—Somnolence—Irinotecan—lung cancer	0.000302	0.000891	CcSEcCtD
Lithium—Headache—Topotecan—lung cancer	0.000301	0.00089	CcSEcCtD
Lithium—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000301	0.00089	CcSEcCtD
Lithium—Rash—Erlotinib—lung cancer	0.0003	0.000886	CcSEcCtD
Lithium—Dermatitis—Erlotinib—lung cancer	0.0003	0.000886	CcSEcCtD
Lithium—Convulsion—Etoposide—lung cancer	0.0003	0.000885	CcSEcCtD
Lithium—Dyspepsia—Irinotecan—lung cancer	0.000299	0.000883	CcSEcCtD
Lithium—Headache—Erlotinib—lung cancer	0.000298	0.000881	CcSEcCtD
Lithium—Loss of consciousness—Paclitaxel—lung cancer	0.000298	0.000881	CcSEcCtD
Lithium—Asthenia—Vinorelbine—lung cancer	0.000295	0.000872	CcSEcCtD
Lithium—Decreased appetite—Irinotecan—lung cancer	0.000295	0.000872	CcSEcCtD
Lithium—Arrhythmia—Docetaxel—lung cancer	0.000295	0.000871	CcSEcCtD
Lithium—Nausea—Vinblastine—lung cancer	0.000294	0.000869	CcSEcCtD
Lithium—Somnolence—Gemcitabine—lung cancer	0.000294	0.000868	CcSEcCtD
Lithium—Convulsion—Paclitaxel—lung cancer	0.000294	0.000868	CcSEcCtD
Lithium—Anorexia—Cisplatin—lung cancer	0.000294	0.000868	CcSEcCtD
Lithium—Fatigue—Irinotecan—lung cancer	0.000293	0.000864	CcSEcCtD
Lithium—Alopecia—Docetaxel—lung cancer	0.000292	0.000862	CcSEcCtD
Lithium—Discomfort—Etoposide—lung cancer	0.000291	0.000859	CcSEcCtD
Lithium—Arthralgia—Paclitaxel—lung cancer	0.000289	0.000853	CcSEcCtD
Lithium—Hypotension—Cisplatin—lung cancer	0.000288	0.000851	CcSEcCtD
Lithium—Decreased appetite—Gemcitabine—lung cancer	0.000287	0.000849	CcSEcCtD
Lithium—Nausea—Topotecan—lung cancer	0.000286	0.000844	CcSEcCtD
Lithium—Discomfort—Paclitaxel—lung cancer	0.000285	0.000843	CcSEcCtD
Lithium—Fatigue—Gemcitabine—lung cancer	0.000285	0.000842	CcSEcCtD
Lithium—Confusional state—Etoposide—lung cancer	0.000285	0.000841	CcSEcCtD
Lithium—Nausea—Erlotinib—lung cancer	0.000283	0.000835	CcSEcCtD
Lithium—Dry mouth—Paclitaxel—lung cancer	0.000282	0.000834	CcSEcCtD
Lithium—Diarrhoea—Vinorelbine—lung cancer	0.000282	0.000832	CcSEcCtD
Lithium—Dysgeusia—Docetaxel—lung cancer	0.000281	0.000832	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000281	0.000829	CcSEcCtD
Lithium—Ataxia—Doxorubicin—lung cancer	0.00028	0.000827	CcSEcCtD
Lithium—Feeling abnormal—Irinotecan—lung cancer	0.00028	0.000826	CcSEcCtD
Lithium—Confusional state—Paclitaxel—lung cancer	0.000279	0.000824	CcSEcCtD
Lithium—Gastrointestinal pain—Irinotecan—lung cancer	0.000277	0.00082	CcSEcCtD
Lithium—Dehydration—Doxorubicin—lung cancer	0.000277	0.000818	CcSEcCtD
Lithium—Oedema—Paclitaxel—lung cancer	0.000277	0.000818	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—lung cancer	0.000274	0.000809	CcSEcCtD
Lithium—Dry skin—Doxorubicin—lung cancer	0.000273	0.000807	CcSEcCtD
Lithium—Feeling abnormal—Gemcitabine—lung cancer	0.000272	0.000805	CcSEcCtD
Lithium—Shock—Paclitaxel—lung cancer	0.000272	0.000804	CcSEcCtD
Lithium—Dizziness—Vinorelbine—lung cancer	0.000272	0.000804	CcSEcCtD
Lithium—Anorexia—Etoposide—lung cancer	0.000269	0.000795	CcSEcCtD
Lithium—Abdominal pain—Irinotecan—lung cancer	0.000268	0.000793	CcSEcCtD
Lithium—Body temperature increased—Irinotecan—lung cancer	0.000268	0.000793	CcSEcCtD
Lithium—Decreased appetite—Cisplatin—lung cancer	0.000268	0.000791	CcSEcCtD
Lithium—Drowsiness—Methotrexate—lung cancer	0.000265	0.000783	CcSEcCtD
Lithium—Anorexia—Paclitaxel—lung cancer	0.000264	0.000779	CcSEcCtD
Lithium—Hypotension—Etoposide—lung cancer	0.000264	0.000779	CcSEcCtD
Lithium—Gastritis—Doxorubicin—lung cancer	0.000264	0.000779	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—lung cancer	0.000263	0.000776	CcSEcCtD
Lithium—Vomiting—Vinorelbine—lung cancer	0.000262	0.000773	CcSEcCtD
Lithium—Body temperature increased—Gemcitabine—lung cancer	0.000261	0.000772	CcSEcCtD
Lithium—Rash—Vinorelbine—lung cancer	0.000259	0.000766	CcSEcCtD
Lithium—Dermatitis—Vinorelbine—lung cancer	0.000259	0.000766	CcSEcCtD
Lithium—Hypotension—Paclitaxel—lung cancer	0.000259	0.000764	CcSEcCtD
Lithium—Headache—Vinorelbine—lung cancer	0.000258	0.000762	CcSEcCtD
Lithium—Syncope—Docetaxel—lung cancer	0.000258	0.000762	CcSEcCtD
Lithium—Feeling abnormal—Cisplatin—lung cancer	0.000254	0.00075	CcSEcCtD
Lithium—Loss of consciousness—Docetaxel—lung cancer	0.000253	0.000746	CcSEcCtD
Lithium—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000252	0.000745	CcSEcCtD
Lithium—Somnolence—Etoposide—lung cancer	0.000251	0.000741	CcSEcCtD
Lithium—Convulsion—Docetaxel—lung cancer	0.000249	0.000736	CcSEcCtD
Lithium—Somnolence—Paclitaxel—lung cancer	0.000246	0.000727	CcSEcCtD
Lithium—Decreased appetite—Etoposide—lung cancer	0.000245	0.000725	CcSEcCtD
Lithium—Arthralgia—Docetaxel—lung cancer	0.000245	0.000723	CcSEcCtD
Lithium—Nausea—Vinorelbine—lung cancer	0.000244	0.000722	CcSEcCtD
Lithium—Dyspepsia—Paclitaxel—lung cancer	0.000244	0.00072	CcSEcCtD
Lithium—Body temperature increased—Cisplatin—lung cancer	0.000244	0.00072	CcSEcCtD
Lithium—Asthenia—Irinotecan—lung cancer	0.000243	0.000719	CcSEcCtD
Lithium—Fatigue—Etoposide—lung cancer	0.000243	0.000719	CcSEcCtD
Lithium—Decreased appetite—Paclitaxel—lung cancer	0.000241	0.000711	CcSEcCtD
Lithium—Dry mouth—Docetaxel—lung cancer	0.000239	0.000707	CcSEcCtD
Lithium—Fatigue—Paclitaxel—lung cancer	0.000239	0.000705	CcSEcCtD
Lithium—Asthenia—Gemcitabine—lung cancer	0.000237	0.000701	CcSEcCtD
Lithium—Confusional state—Docetaxel—lung cancer	0.000237	0.000699	CcSEcCtD
Lithium—Oedema—Docetaxel—lung cancer	0.000235	0.000693	CcSEcCtD
Lithium—Weight increased—Doxorubicin—lung cancer	0.000234	0.000692	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—lung cancer	0.000233	0.000688	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—lung cancer	0.000233	0.000687	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—lung cancer	0.000232	0.000686	CcSEcCtD
Lithium—Diarrhoea—Irinotecan—lung cancer	0.000232	0.000686	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—lung cancer	0.000231	0.000682	CcSEcCtD
Lithium—Shock—Docetaxel—lung cancer	0.000231	0.000682	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—lung cancer	0.00023	0.000678	CcSEcCtD
Lithium—Feeling abnormal—Paclitaxel—lung cancer	0.000228	0.000674	CcSEcCtD
Lithium—Gastrointestinal pain—Paclitaxel—lung cancer	0.000226	0.000669	CcSEcCtD
Lithium—Diarrhoea—Gemcitabine—lung cancer	0.000226	0.000668	CcSEcCtD
Lithium—Dizziness—Irinotecan—lung cancer	0.000224	0.000663	CcSEcCtD
Lithium—Anorexia—Docetaxel—lung cancer	0.000224	0.000661	CcSEcCtD
Lithium—Abdominal pain—Etoposide—lung cancer	0.000223	0.000659	CcSEcCtD
Lithium—Body temperature increased—Etoposide—lung cancer	0.000223	0.000659	CcSEcCtD
Lithium—Tinnitus—Methotrexate—lung cancer	0.000222	0.000656	CcSEcCtD
Lithium—Asthenia—Cisplatin—lung cancer	0.000221	0.000653	CcSEcCtD
Lithium—Hypotension—Docetaxel—lung cancer	0.000219	0.000648	CcSEcCtD
Lithium—Body temperature increased—Paclitaxel—lung cancer	0.000219	0.000646	CcSEcCtD
Lithium—Abdominal pain—Paclitaxel—lung cancer	0.000219	0.000646	CcSEcCtD
Lithium—Vomiting—Irinotecan—lung cancer	0.000216	0.000637	CcSEcCtD
Lithium—Rash—Irinotecan—lung cancer	0.000214	0.000632	CcSEcCtD
Lithium—Dermatitis—Irinotecan—lung cancer	0.000214	0.000632	CcSEcCtD
Lithium—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000214	0.000631	CcSEcCtD
Lithium—Headache—Irinotecan—lung cancer	0.000213	0.000628	CcSEcCtD
Lithium—Diarrhoea—Cisplatin—lung cancer	0.000211	0.000623	CcSEcCtD
Lithium—Alopecia—Methotrexate—lung cancer	0.00021	0.000621	CcSEcCtD
Lithium—Vomiting—Gemcitabine—lung cancer	0.00021	0.000621	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—lung cancer	0.00021	0.00062	CcSEcCtD
Lithium—Somnolence—Docetaxel—lung cancer	0.000209	0.000616	CcSEcCtD
Lithium—Rash—Gemcitabine—lung cancer	0.000208	0.000616	CcSEcCtD
Lithium—Dermatitis—Gemcitabine—lung cancer	0.000208	0.000615	CcSEcCtD
Lithium—Headache—Gemcitabine—lung cancer	0.000207	0.000612	CcSEcCtD
Lithium—Dyspepsia—Docetaxel—lung cancer	0.000206	0.00061	CcSEcCtD
Lithium—Decreased appetite—Docetaxel—lung cancer	0.000204	0.000602	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—lung cancer	0.000203	0.000599	CcSEcCtD
Lithium—Asthenia—Etoposide—lung cancer	0.000203	0.000598	CcSEcCtD
Lithium—Fatigue—Docetaxel—lung cancer	0.000202	0.000598	CcSEcCtD
Lithium—Nausea—Irinotecan—lung cancer	0.000202	0.000596	CcSEcCtD
Lithium—Asthenia—Paclitaxel—lung cancer	0.000199	0.000587	CcSEcCtD
Lithium—Nausea—Gemcitabine—lung cancer	0.000196	0.00058	CcSEcCtD
Lithium—Vomiting—Cisplatin—lung cancer	0.000196	0.000579	CcSEcCtD
Lithium—Vision blurred—Methotrexate—lung cancer	0.000195	0.000577	CcSEcCtD
Lithium—Rash—Cisplatin—lung cancer	0.000194	0.000574	CcSEcCtD
Lithium—Dermatitis—Cisplatin—lung cancer	0.000194	0.000573	CcSEcCtD
Lithium—Feeling abnormal—Docetaxel—lung cancer	0.000193	0.000571	CcSEcCtD
Lithium—Diarrhoea—Etoposide—lung cancer	0.000193	0.000571	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—lung cancer	0.000192	0.000568	CcSEcCtD
Lithium—Gastrointestinal pain—Docetaxel—lung cancer	0.000192	0.000567	CcSEcCtD
Lithium—Diarrhoea—Paclitaxel—lung cancer	0.000189	0.000559	CcSEcCtD
Lithium—Dizziness—Etoposide—lung cancer	0.000187	0.000551	CcSEcCtD
Lithium—Vertigo—Methotrexate—lung cancer	0.000186	0.00055	CcSEcCtD
Lithium—Abdominal pain—Docetaxel—lung cancer	0.000185	0.000548	CcSEcCtD
Lithium—Body temperature increased—Docetaxel—lung cancer	0.000185	0.000548	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—lung cancer	0.000184	0.000544	CcSEcCtD
Lithium—Dizziness—Paclitaxel—lung cancer	0.000183	0.000541	CcSEcCtD
Lithium—Nausea—Cisplatin—lung cancer	0.000183	0.000541	CcSEcCtD
Lithium—Alopecia—Doxorubicin—lung cancer	0.000182	0.000538	CcSEcCtD
Lithium—Convulsion—Methotrexate—lung cancer	0.000179	0.00053	CcSEcCtD
Lithium—Vomiting—Etoposide—lung cancer	0.000179	0.00053	CcSEcCtD
Lithium—Rash—Etoposide—lung cancer	0.000178	0.000526	CcSEcCtD
Lithium—Dermatitis—Etoposide—lung cancer	0.000178	0.000525	CcSEcCtD
Lithium—Headache—Etoposide—lung cancer	0.000177	0.000522	CcSEcCtD
Lithium—Flatulence—Doxorubicin—lung cancer	0.000177	0.000522	CcSEcCtD
Lithium—Arthralgia—Methotrexate—lung cancer	0.000176	0.000521	CcSEcCtD
Lithium—Vomiting—Paclitaxel—lung cancer	0.000176	0.00052	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—lung cancer	0.000176	0.000519	CcSEcCtD
Lithium—Rash—Paclitaxel—lung cancer	0.000174	0.000516	CcSEcCtD
Lithium—Dermatitis—Paclitaxel—lung cancer	0.000174	0.000515	CcSEcCtD
Lithium—Discomfort—Methotrexate—lung cancer	0.000174	0.000515	CcSEcCtD
Lithium—Headache—Paclitaxel—lung cancer	0.000173	0.000512	CcSEcCtD
Lithium—Confusional state—Methotrexate—lung cancer	0.00017	0.000504	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—lung cancer	0.000169	0.000499	CcSEcCtD
Lithium—Asthenia—Docetaxel—lung cancer	0.000168	0.000497	CcSEcCtD
Lithium—Nausea—Etoposide—lung cancer	0.000168	0.000495	CcSEcCtD
Lithium—Agitation—Doxorubicin—lung cancer	0.000165	0.000487	CcSEcCtD
Lithium—Nausea—Paclitaxel—lung cancer	0.000164	0.000486	CcSEcCtD
Lithium—Vertigo—Doxorubicin—lung cancer	0.000161	0.000476	CcSEcCtD
Lithium—Anorexia—Methotrexate—lung cancer	0.000161	0.000476	CcSEcCtD
Lithium—Syncope—Doxorubicin—lung cancer	0.000161	0.000475	CcSEcCtD
Lithium—Diarrhoea—Docetaxel—lung cancer	0.00016	0.000474	CcSEcCtD
Lithium—Hypotension—Methotrexate—lung cancer	0.000158	0.000467	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—lung cancer	0.000158	0.000466	CcSEcCtD
Lithium—Convulsion—Doxorubicin—lung cancer	0.000155	0.000459	CcSEcCtD
Lithium—Dizziness—Docetaxel—lung cancer	0.000155	0.000458	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000154	0.000455	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—lung cancer	0.000153	0.000451	CcSEcCtD
Lithium—Discomfort—Doxorubicin—lung cancer	0.000151	0.000446	CcSEcCtD
Lithium—Somnolence—Methotrexate—lung cancer	0.00015	0.000444	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—lung cancer	0.000149	0.000441	CcSEcCtD
Lithium—Vomiting—Docetaxel—lung cancer	0.000149	0.000441	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—lung cancer	0.000149	0.00044	CcSEcCtD
Lithium—Rash—Docetaxel—lung cancer	0.000148	0.000437	CcSEcCtD
Lithium—Dermatitis—Docetaxel—lung cancer	0.000148	0.000437	CcSEcCtD
Lithium—Confusional state—Doxorubicin—lung cancer	0.000148	0.000436	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—lung cancer	0.000147	0.000434	CcSEcCtD
Lithium—Headache—Docetaxel—lung cancer	0.000147	0.000434	CcSEcCtD
Lithium—Oedema—Doxorubicin—lung cancer	0.000146	0.000433	CcSEcCtD
Lithium—Fatigue—Methotrexate—lung cancer	0.000146	0.000431	CcSEcCtD
Lithium—Shock—Doxorubicin—lung cancer	0.000144	0.000426	CcSEcCtD
Lithium—Anorexia—Doxorubicin—lung cancer	0.00014	0.000412	CcSEcCtD
Lithium—Nausea—Docetaxel—lung cancer	0.000139	0.000412	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—lung cancer	0.000139	0.000412	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—lung cancer	0.000138	0.000408	CcSEcCtD
Lithium—Hypotension—Doxorubicin—lung cancer	0.000137	0.000404	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—lung cancer	0.000134	0.000395	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—lung cancer	0.000134	0.000395	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000133	0.000394	CcSEcCtD
Lithium—Somnolence—Doxorubicin—lung cancer	0.00013	0.000385	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—lung cancer	0.000129	0.000381	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—lung cancer	0.000127	0.000376	CcSEcCtD
Lithium—Fatigue—Doxorubicin—lung cancer	0.000126	0.000373	CcSEcCtD
Lithium—Asthenia—Methotrexate—lung cancer	0.000121	0.000358	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—lung cancer	0.000121	0.000356	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—lung cancer	0.00012	0.000354	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—lung cancer	0.000116	0.000342	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—lung cancer	0.000116	0.000342	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—lung cancer	0.000116	0.000342	CcSEcCtD
Lithium—Dizziness—Methotrexate—lung cancer	0.000112	0.00033	CcSEcCtD
Lithium—Vomiting—Methotrexate—lung cancer	0.000107	0.000318	CcSEcCtD
Lithium—Rash—Methotrexate—lung cancer	0.000107	0.000315	CcSEcCtD
Lithium—Dermatitis—Methotrexate—lung cancer	0.000106	0.000315	CcSEcCtD
Lithium—Headache—Methotrexate—lung cancer	0.000106	0.000313	CcSEcCtD
Lithium—Asthenia—Doxorubicin—lung cancer	0.000105	0.00031	CcSEcCtD
Lithium—Nausea—Methotrexate—lung cancer	0.0001	0.000297	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—lung cancer	0.0001	0.000296	CcSEcCtD
Lithium—Dizziness—Doxorubicin—lung cancer	9.68e-05	0.000286	CcSEcCtD
Lithium—Vomiting—Doxorubicin—lung cancer	9.31e-05	0.000275	CcSEcCtD
Lithium—Rash—Doxorubicin—lung cancer	9.23e-05	0.000273	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—lung cancer	9.22e-05	0.000272	CcSEcCtD
Lithium—Headache—Doxorubicin—lung cancer	9.17e-05	0.000271	CcSEcCtD
Lithium—Nausea—Doxorubicin—lung cancer	8.7e-05	0.000257	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—FGF9—lung cancer	3.84e-05	7.62e-05	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—lung cancer	3.83e-05	7.59e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—lung cancer	3.82e-05	7.58e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—lung cancer	3.82e-05	7.57e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERCC2—lung cancer	3.8e-05	7.54e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—lung cancer	3.78e-05	7.5e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6R—lung cancer	3.77e-05	7.48e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CREBBP—lung cancer	3.77e-05	7.47e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGFR1—lung cancer	3.75e-05	7.43e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—lung cancer	3.75e-05	7.43e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—lung cancer	3.74e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—lung cancer	3.74e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB3—lung cancer	3.72e-05	7.37e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—lung cancer	3.71e-05	7.35e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—lung cancer	3.71e-05	7.35e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—lung cancer	3.7e-05	7.33e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—lung cancer	3.69e-05	7.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUNB—lung cancer	3.67e-05	7.27e-05	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—lung cancer	3.67e-05	7.27e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAP2K1—lung cancer	3.6e-05	7.13e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK3—lung cancer	3.58e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CD—lung cancer	3.57e-05	7.08e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—lung cancer	3.57e-05	7.07e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—lung cancer	3.56e-05	7.06e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—lung cancer	3.55e-05	7.04e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—lung cancer	3.53e-05	7e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—lung cancer	3.53e-05	6.99e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB3—lung cancer	3.53e-05	6.99e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MDM2—lung cancer	3.47e-05	6.87e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR1—lung cancer	3.46e-05	6.86e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—RAF1—lung cancer	3.46e-05	6.85e-05	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—lung cancer	3.45e-05	6.84e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—lung cancer	3.44e-05	6.82e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—lung cancer	3.43e-05	6.8e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—lung cancer	3.42e-05	6.78e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—lung cancer	3.41e-05	6.76e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—lung cancer	3.4e-05	6.75e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—lung cancer	3.39e-05	6.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—lung cancer	3.38e-05	6.7e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MTOR—lung cancer	3.37e-05	6.69e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—lung cancer	3.37e-05	6.69e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—lung cancer	3.37e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STK11—lung cancer	3.33e-05	6.6e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—lung cancer	3.3e-05	6.54e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—lung cancer	3.29e-05	6.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APOA1—lung cancer	3.29e-05	6.52e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR1—lung cancer	3.28e-05	6.5e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—lung cancer	3.27e-05	6.48e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—lung cancer	3.25e-05	6.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—lung cancer	3.23e-05	6.41e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGF—lung cancer	3.22e-05	6.38e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—lung cancer	3.22e-05	6.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FOXO3—lung cancer	3.22e-05	6.37e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—lung cancer	3.2e-05	6.35e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—RAF1—lung cancer	3.19e-05	6.32e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—lung cancer	3.17e-05	6.28e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK3—lung cancer	3.16e-05	6.26e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—lung cancer	3.16e-05	6.26e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—lung cancer	3.14e-05	6.22e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—lung cancer	3.13e-05	6.2e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOA1—lung cancer	3.12e-05	6.18e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—lung cancer	3.11e-05	6.17e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MTOR—lung cancer	3.11e-05	6.17e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—lung cancer	3.11e-05	6.16e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—lung cancer	3.1e-05	6.14e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—lung cancer	3.09e-05	6.13e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—lung cancer	3.09e-05	6.12e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—lung cancer	3.03e-05	6.01e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6R—lung cancer	3.02e-05	5.99e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREBBP—lung cancer	3.02e-05	5.98e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—lung cancer	3.01e-05	5.98e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AVP—lung cancer	3.01e-05	5.97e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—lung cancer	3.01e-05	5.96e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KIT—lung cancer	3e-05	5.95e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—lung cancer	3e-05	5.95e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—lung cancer	2.99e-05	5.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGF—lung cancer	2.97e-05	5.89e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—lung cancer	2.92e-05	5.79e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—lung cancer	2.92e-05	5.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—lung cancer	2.9e-05	5.75e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—lung cancer	2.89e-05	5.72e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—lung cancer	2.88e-05	5.72e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAP2K1—lung cancer	2.88e-05	5.71e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—lung cancer	2.86e-05	5.67e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—lung cancer	2.85e-05	5.65e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—lung cancer	2.85e-05	5.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIT—lung cancer	2.85e-05	5.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—lung cancer	2.85e-05	5.64e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—lung cancer	2.84e-05	5.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—lung cancer	2.82e-05	5.6e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGF—lung cancer	2.81e-05	5.58e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6R—lung cancer	2.79e-05	5.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CREBBP—lung cancer	2.78e-05	5.52e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—lung cancer	2.78e-05	5.51e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—lung cancer	2.77e-05	5.49e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—lung cancer	2.73e-05	5.42e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—lung cancer	2.73e-05	5.41e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—POMC—lung cancer	2.71e-05	5.37e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—lung cancer	2.7e-05	5.36e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—lung cancer	2.7e-05	5.35e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—lung cancer	2.69e-05	5.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—lung cancer	2.68e-05	5.3e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAP2K1—lung cancer	2.66e-05	5.27e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6R—lung cancer	2.64e-05	5.24e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—lung cancer	2.64e-05	5.23e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREBBP—lung cancer	2.64e-05	5.23e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—lung cancer	2.62e-05	5.19e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—lung cancer	2.61e-05	5.17e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—lung cancer	2.61e-05	5.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB3—lung cancer	2.6e-05	5.16e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—lung cancer	2.6e-05	5.16e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—lung cancer	2.57e-05	5.09e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MDM2—lung cancer	2.56e-05	5.08e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAF1—lung cancer	2.55e-05	5.06e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—lung cancer	2.53e-05	5.01e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAP2K1—lung cancer	2.52e-05	4.99e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—lung cancer	2.51e-05	4.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—lung cancer	2.5e-05	4.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—lung cancer	2.5e-05	4.95e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—lung cancer	2.5e-05	4.95e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MTOR—lung cancer	2.49e-05	4.94e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—lung cancer	2.49e-05	4.94e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK3—lung cancer	2.49e-05	4.94e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—lung cancer	2.49e-05	4.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR1—lung cancer	2.42e-05	4.81e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—lung cancer	2.41e-05	4.79e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—lung cancer	2.41e-05	4.78e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—lung cancer	2.41e-05	4.77e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—lung cancer	2.4e-05	4.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—lung cancer	2.39e-05	4.73e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—lung cancer	2.37e-05	4.7e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—lung cancer	2.37e-05	4.69e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—RAF1—lung cancer	2.36e-05	4.67e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—lung cancer	2.33e-05	4.62e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—lung cancer	2.32e-05	4.6e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—lung cancer	2.31e-05	4.58e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOA1—lung cancer	2.3e-05	4.57e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTOR—lung cancer	2.3e-05	4.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—lung cancer	2.3e-05	4.56e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK3—lung cancer	2.3e-05	4.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—lung cancer	2.3e-05	4.55e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—lung cancer	2.29e-05	4.54e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—lung cancer	2.28e-05	4.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—lung cancer	2.28e-05	4.52e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—lung cancer	2.24e-05	4.44e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—lung cancer	2.24e-05	4.44e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—lung cancer	2.24e-05	4.43e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAF1—lung cancer	2.23e-05	4.43e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—lung cancer	2.23e-05	4.42e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—lung cancer	2.21e-05	4.38e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—lung cancer	2.19e-05	4.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MTOR—lung cancer	2.18e-05	4.32e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—lung cancer	2.18e-05	4.32e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—lung cancer	2.16e-05	4.28e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—lung cancer	2.15e-05	4.27e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—lung cancer	2.13e-05	4.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—lung cancer	2.1e-05	4.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—lung cancer	2.1e-05	4.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—lung cancer	2.1e-05	4.17e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—lung cancer	2.1e-05	4.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGF—lung cancer	2.08e-05	4.12e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—lung cancer	2.07e-05	4.1e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—lung cancer	2.06e-05	4.08e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—lung cancer	2.05e-05	4.07e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—lung cancer	2.05e-05	4.06e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—lung cancer	2.01e-05	3.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—lung cancer	2e-05	3.97e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—POMC—lung cancer	2e-05	3.97e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—lung cancer	2e-05	3.96e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—lung cancer	1.99e-05	3.95e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—lung cancer	1.99e-05	3.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—lung cancer	1.98e-05	3.92e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6R—lung cancer	1.95e-05	3.87e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—lung cancer	1.95e-05	3.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREBBP—lung cancer	1.95e-05	3.87e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—lung cancer	1.95e-05	3.86e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—lung cancer	1.93e-05	3.82e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—lung cancer	1.92e-05	3.81e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—lung cancer	1.9e-05	3.77e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—lung cancer	1.9e-05	3.76e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—lung cancer	1.9e-05	3.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—lung cancer	1.9e-05	3.76e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—lung cancer	1.89e-05	3.75e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—lung cancer	1.88e-05	3.74e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAP2K1—lung cancer	1.86e-05	3.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—lung cancer	1.85e-05	3.67e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—lung cancer	1.84e-05	3.66e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK3—lung cancer	1.84e-05	3.65e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—lung cancer	1.82e-05	3.61e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—lung cancer	1.8e-05	3.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—lung cancer	1.78e-05	3.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—lung cancer	1.77e-05	3.52e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—lung cancer	1.76e-05	3.48e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—lung cancer	1.75e-05	3.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—lung cancer	1.75e-05	3.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—lung cancer	1.7e-05	3.37e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK3—lung cancer	1.7e-05	3.37e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—lung cancer	1.69e-05	3.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—lung cancer	1.68e-05	3.33e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—lung cancer	1.68e-05	3.33e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—lung cancer	1.68e-05	3.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—lung cancer	1.66e-05	3.28e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—lung cancer	1.65e-05	3.28e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—lung cancer	1.65e-05	3.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RAF1—lung cancer	1.65e-05	3.27e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—lung cancer	1.63e-05	3.24e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—lung cancer	1.62e-05	3.2e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—lung cancer	1.61e-05	3.2e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MTOR—lung cancer	1.61e-05	3.2e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK3—lung cancer	1.61e-05	3.19e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—lung cancer	1.57e-05	3.11e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—lung cancer	1.55e-05	3.08e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—lung cancer	1.55e-05	3.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—lung cancer	1.53e-05	3.04e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—lung cancer	1.53e-05	3.03e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—lung cancer	1.52e-05	3.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—lung cancer	1.48e-05	2.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—lung cancer	1.48e-05	2.93e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—lung cancer	1.45e-05	2.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—lung cancer	1.44e-05	2.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—lung cancer	1.44e-05	2.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—lung cancer	1.41e-05	2.79e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—lung cancer	1.4e-05	2.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—lung cancer	1.4e-05	2.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—lung cancer	1.4e-05	2.77e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—lung cancer	1.39e-05	2.76e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—lung cancer	1.35e-05	2.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—lung cancer	1.33e-05	2.64e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—lung cancer	1.33e-05	2.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—lung cancer	1.3e-05	2.57e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—lung cancer	1.29e-05	2.56e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—lung cancer	1.29e-05	2.55e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—lung cancer	1.26e-05	2.49e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—lung cancer	1.25e-05	2.47e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—lung cancer	1.24e-05	2.46e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—lung cancer	1.24e-05	2.46e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—lung cancer	1.24e-05	2.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—lung cancer	1.23e-05	2.44e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK3—lung cancer	1.19e-05	2.36e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—lung cancer	1.18e-05	2.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—lung cancer	1.16e-05	2.29e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—lung cancer	1.15e-05	2.27e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—lung cancer	1.13e-05	2.24e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—lung cancer	1.09e-05	2.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—lung cancer	1.07e-05	2.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—lung cancer	9.83e-06	1.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—lung cancer	9.51e-06	1.88e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—lung cancer	9.09e-06	1.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—lung cancer	8.7e-06	1.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—lung cancer	8.03e-06	1.59e-05	CbGpPWpGaD
